TORNTPHARM Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,178 Cr
verified against source
Revenue YoY
11%
reported change
EBITDA
₹1,032 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered a 11% revenue growth to INR 3,178 crore in Q1 FY26, driven by strong branded market performance (72% of revenue). Operating EBITDA grew 14% to INR 1,032 crore with underlying margin of 32.9%, while Brazil (16% CC growth) and India (11% growth) outperformed their respective markets. The U.S. business grew 19% but remains loss-making with losses expected to decline sequentially. Germany faced third-party supply disruption impacting growth to just 1% in CC terms, with resolution expected over a couple of quarters. Field force expansion continues with 6,600 MRs now, targeting 6,900-7,000 by year-end. JB Pharma acquisition remains on track for regulatory approvals. Key risks include currency headwinds (INR 48 crore forex loss), ongoing U.S. losses, and Germany supply normalization uncertainty. Management guided minimum 32.9% EBITDA margin sustaining through FY26.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects the adjusted operating margin of 32.9% (excluding INR 15 crore one-off acquisition expense) to be the floor for all remaining quarters, with potential upside from operating leverage.
- India field force expansion continues with ~200 MR additions per quarter, focusing on chronic segment expansion and new division coverage.
- First quarter saw 4-5 launches including esomeprazole granules and sacubitril; another 5-6 launches expected in remaining quarters to drive revenue growth.
- Three divisions in Brazil each targeting 2-3 launches annually, supported by 62 molecules in approval queue with varying timelines.
Risks flagged
- Third-party supplier regulatory issues affecting 75% of German business; management cannot predict resolution but expects impact for at least a couple of quarters, capping growth at low single digits.
- Despite improved facility performance and contract wins, U.S. operations continue to post losses; management expects losses to decline quarter-on-quarter but profitability remains distant.
- Brazilian real depreciated ~15% last fiscal year and has since appreciated 10%, leaving a residual 5% currency headwind between constant currency and INR-reported growth for the quarter.
- Analyst raised concerns about 1,000 MR additions over one year while growth rates haven't proportionally increased; management responded that MR additions take 12-18 months to show impact and emphasized 2-year horizon for evaluating expansion ROI.
Key quotes
- Minimum what we have reported in quarter one should continue for the rest of the quarters.
- We are the fifth-largest generic company with about 6% of the German generic market. We have an aggressive growth strategy in terms of new launches and cost improvements of existing portfolio.
- The MR additions take at least 12-18 months to onboard and kind of get familiarized... It is best to look at it from a two-year horizon rather than anything shorter than that.
Research modules